Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care

• Published in: Cancer chemotherapy and pharmacology Vol. 61; no. 6; pp. 903 - 909
• Main Authors: Launay-Vacher, Vincent, Rey, Jean-Baptiste, Isnard-Bagnis, Corinne, Deray, Gilbert, Daouphars, Mikael
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer-Verlag 01.05.2008; Springer; Springer Nature B.V
• Subjects: Antineoplastic agents; Antineoplastic Agents - adverse effects; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Cancer Research; Cisplatin - adverse effects; Cisplatin - pharmacology; Cisplatin - therapeutic use; Humans; Kidney Diseases - chemically induced; Kidney Diseases - prevention & control; Medical sciences; Medicine; Medicine & Public Health; Neoplasms - complications; Neoplasms - drug therapy; Oncology; Pharmacology. Drug treatments; Pharmacology/Toxicology; Review; Europe; Platinum salts; Cisplatin; Renal toxicity; Antineoplastic agent; State of the art; Urinary system disease; Toxicity; Malignant tumor; Platinum complex; Hospital pharmacy; Recommendation; Kidney; Care; Prevention; Alkylating agent; Urinary system; Cancer; Platinum II Complexes
• ISSN: 0344-5704; 1432-0843
• DOI: 10.1007/s00280-008-0711-0

Antineoplastic drugs used in the treatment of cancers present with variable renal tolerance profiles. Among drugs with a potential for renal toxicity, platinum salts, and especially cisplatin is a well-known agent that may induce acute and chronic renal failure. The mechanisms of its renal toxicity and the means of its prevention are presented in this article which represent the Clinical Recommendation from the Special Interest Group on Cancer Care of the European Society of Clinical Pharmacy (ESCP).